Low Encapsulation Efficiency: Free Actives & Label Claim
Liposomal delivery shields the active compounds inside phospholipid bilayers. However, an ingredient list claiming ‘liposomal’ does not guarantee true delivery. Encapsulation efficiency percentage (EE%) determines quality. When a batch falls short of quality parameters and exhibits low EE%, the active ingredients remain unencapsulated as free active in solution, causing rapid chemical degradation, stomach irritation, and early loss of potency. Eventually, finished products fail to meet specified label claims, exposing supplement brands, formulators, and contract manufacturers to severe regulatory risks and lost consumer trust. Rigorous verification of encapsulation rates is crucial for compliance.
Key Takeaways
- Encapsulation Efficiency (EE%) measures active payload trapped inside lipid vesicles versus unencapsulated free active.
- Free active compounds degrade rapidly, causing potency loss and unsuccessful regulatory label claims.
- Causes of low encapsulation efficiency include insufficient shear energy, poor phospholipid selection, and unoptimised phase transition temperatures.
- Verifying EE% during quality control requires physical separation techniques including ultracentrifugation, HPLC, or Dynamic Light Scattering.
Quick Answer. Low Encapsulation Efficiency leaves free payload to degrade rapidly. Encapsulation efficiency above 70% is essential for verified product stability.
How Low Encapsulation Efficiency Undermines Formulations
Adding lecithin to a liquid formula does not create a functional nanocarrier. The core performance metric of a lipid system is its encapsulation efficiency percentage. When a batch exhibits low EE, the carrier architecture fails, leaving most active ingredients suspended as unencapsulated free active.
Unencapsulated free active acts like standard, unformulated raw material. Stomach acid and digestive enzymes break down these unprotected active ingredients. Sensitive nutrients like glutathione, iron, or vitamin C lose their potency before reaching absorption sites.
Causes of Low Encapsulation Efficiency in Liposomal Manufacturing
Achieving high encapsulation efficiency requires precise control of thermal, mechanical, and chemical variables during synthesis. Formulators must identify root causes of low EE when moving from laboratory prototypes to commercial production scale.
Here are two major causes for low encapsulation efficiency in liposomal manufacturing:
1. Process Dynamics and Homogenisation Parameters
Assembling uniform lipid bilayers needs exact energy input. Low homogenisation pressure yields large, unstable multilamellar vesicles with poor entrapment volume. Conversely, excessive shear energy or heat spikes without proper cooling can disrupt lipid bilayers, causing leakage of trapped payloads into the surrounding solution [1].
2. Phospholipid Selection and Active Interactions
Chemical compatibility between lipid carriers and target active molecules dictates successful entrapment. Hydrophilic active ingredients need large aqueous cores, while hydrophobic compounds fit inside fatty acid bilayers. Poor lipid ratios, low-purity lecithin, or incorrect membrane phase-transition temperatures cause structural instability, leading to payload expulsion and rapid membrane collapse.
Critical Industry Consequences of Free Actives
Unencapsulated actives create severe quality, regulatory, and commercial challenges for finished products across four major operational areas:
- Formulation Stability & Integrity: Non-entrapped ingredients remain directly exposed to oxygen, light, and moisture, accelerating oxidation and active breakdown during storage.
- Quality Assurance & Regulatory Compliance: When free actives degrade in solution, overall product potency drops rapidly, leading to failed label claims and non-compliance during stability audits.
- Consumer Experience & Clinical Tolerance: Unencapsulated minerals or harsh actives contact mucosal tissue or stomach walls directly, triggering nausea, metallic tastes, and digestive complaints.
- Economic & Cost Management: Formulators must add excess active payloads to offset degradation losses. High encapsulation efficiency achieves target clinical efficacy using lower active raw material inputs.
What Unencapsulated Active Does to Your Label Claim and Quality Control
The risks of unencapsulated actives appear during stability testing and regulatory reviews. Non-entrapped ingredients in liquid solution undergo photo-oxidation and chemical hydrolysis. Over a standard 24 months shelf life, total potency falls below package label claims.
Brands should enforce EE% quality-control protocols for liposomal products during routine batch testing. Measuring total active content with standard HPLC is misleading, since total assay counts both encapsulated and free active together. Quality control needs physical separation such as ultracentrifugation, solid-phase extraction, or dialysis to isolate encapsulated active [2]. Without verified EE% testing, brands risk shipping non-compliant products.
What is a Good Encapsulation Efficiency Percentage?
Buyers and formulators often ask where the commercial threshold sits. In commercial manufacturing, an EE% > 70% represents the industry benchmark. The table below specifies standard performance metrics across key ingredient categories:
| Active Category | Target EE% Benchmark | Free Active Risk Level | Commercial Stability Impact |
| Hydrophilic Actives (e.g., Vitamin C, Glutathione) |
> 70% | High (Rapid Hydrolysis) | Guarantees full shelf-life potency and prevents stomach irritation. |
| Lipophilic Actives (e.g., Curcumin, CoQ10) |
> 70% | Moderate (Precipitation) | Prevents active crystallisation and maintains high absorption. |
| Mineral Complexes (e.g., Liposomal Iron, Magnesium) |
> 70% | High (Metallic Taste / GI) | Eliminates metallic taste and digestive discomfort. |
| Sub-Standard Formulations (Unoptimised Liposomes) |
< 60% (Low EE%) | Severe (High unencapsulated Active) | Rapid potency drop, failed label claims, and customer complaints. |
WBCIL’s Expertise in Bulk Liposomal API Manufacturing
West Bengal Chemical Industries Limited (WBCIL) specialises in pharmaceutical-grade APIs. It maintains high encapsulation efficiency across commercial batches by using advanced high-pressure microfluidisation and precise thermal controls. It operates under WHO-GMP / cGMP / ISO standards with automated liposomal product quality control EE% testing. By offering verified Certificates of Analysis and complete batch traceability, WBCIL helps global brands eliminate unencapsulated active degradation, protect label claims, and deliver superior clinical outcomes.
Final Thoughts
Low EE% risks supplement stability, label accuracy, and brand reputation. Unencapsulated free active turns advanced liposomal claims into standard, rapidly degrading products. Partnering with a specialised manufacturer ensures high encapsulation efficiency through validated processing and thorough quality control. Shielding your active ingredients with verified entrapment is the smartest way to secure label claims, meet regulatory standards, and maintain sustained consumer trust.
- Dinić S, Arambašić Jovanović J, Uskoković A, Jovanović A, Grdović N, Rajić J, Đorđević M, Sarić A, Bugarski B, Vidaković M, Mihailović M. Liposome encapsulation enhances the antidiabetic efficacy of silibinin. Pharmaceutics. 2024 Jun 13;16(6):801.
- Wang JP, Huang ZR, Zhang C, Ni YR, Li BT, Wang Y, Wu JF. Methodological advances in liposomal encapsulation efficiency determination: systematic review and analysis. Journal of Drug Targeting. 2025 Sep 14;33(8):1262-71.
Low EE means that a large fraction of the active ingredient remains unencapsulated as free payload outside lipid vesicles. This unshielded active ingredient degrades rapidly, reducing product shelf life and causing failed label claims.
Main causes of low EE include incorrect lipid ratios, low homogenisation pressure, thermal stress, and incompatible lipid selection. Unmatched phase-transition temperatures can also cause lipid membranes to leak payloads.
Free active distorts basic assay results because standard HPLC measures total active content rather than true entrapment. Thorough quality control requires ultracentrifugation or solid-phase extraction to separate free active before testing.
A good encapsulation efficiency percentage for commercial liposomal supplements is >70%. This level ensures payload protection, extended shelf life, and full compliance with package label claims.
High EE% requires matched homogenisation pressure, controlled phase-transition temperatures, and separation-based verification for every batch. WBCIL achieves this through validated high-pressure microfluidisation and ultracentrifugation-based EE% testing, with Certificates of Analysis confirming >70% active entrapment per batch.
